Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.38 |
| ▸ | DRD2 | P14416 | 5/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD1 | P21728 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5351711 | 0.83 | MTNR1A (0.51) | MTNR1ATRPV1MTNR1BDRD2SLC6A4 | |
| SCHEMBL5344436 | 0.83 | MTNR1A (0.50) | MTNR1ATRPV1MTNR1BDRD2SLC6A4 | |
| SCHEMBL9627709 | 0.76 | BRD4 (0.36) | DRD2SLC6A4BRD4CREBBP | |
| SCHEMBL5228827 | 0.68 | MTNR1A (1.00) | MTNR1AMTNR1BHTR2B | |
| SCHEMBL19658437 | 0.68 | MTNR1A (0.65) | MTNR1AMTNR1B | |
| SCHEMBL5344278 | 0.68 | MTNR1A (0.72) | MTNR1ATRPV1MTNR1B | |
| SCHEMBL6076652 | 0.67 | MTNR1A (0.70) | MTNR1ATRPV1MTNR1B | |
| SCHEMBL5334595 | 0.67 | MTNR1A (0.70) | MTNR1ATRPV1MTNR1B | |
| SCHEMBL5346519 | 0.67 | MTNR1A (0.70) | MTNR1ATRPV1MTNR1B | |
| SCHEMBL5346165 | 0.67 | MTNR1A (0.70) | MTNR1ATRPV1MTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183318-B2 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2007-02-27 | — | — | US | disclosed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-6605632-B1 | Affinity for melatonin receptors | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP4B1, CYP3A5, MC2R | MTNR1A 388/4885TRPV1 2408/4885MTNR1B 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.